Table 1.
Patient baseline characteristics.
| Variable | Galunisertib (any formulation) N=14 |
|---|---|
| Age, years | |
| Mean | 59.8 |
| Median (range) | 56.5 (34–76) |
|
| |
| Sex, n (%) | |
| Female | 9 (64.0) |
| Male | 5 (36.0) |
|
| |
| Origin, n (%) | |
| Caucasian | 14 (100) |
|
| |
| ECOG performance status, n (%) | |
| 0 | 4 (28.6) |
| 1 | 8 (57.1) |
| 2 | 2 (14.3) |
|
| |
| Initial pathological diagnosis, n (%) | |
| Astrocytoma | 2 (14.3) |
| Choroidal melanoma | 1 (7.1) |
| Colon adenocarcinoma | 1 (7.1) |
| Glioblastoma | 7 (50.0) |
| Hepatocellular carcinoma | 2 (14.2) |
| Pancreatic adenocarcinoma | 1 (7.1) |
|
| |
| Stage of disease at study entry, n (%) | |
| Metastatic | 3 (21.4) |
| Recurrent | 11 (78.6) |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; N = number of patients who received drug.